Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | MicrobiomeTrials← Back to trialsNCT01841723
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2013-04-30Est. Completion: 2029-12-31
Enrollment target: 44 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- UT MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Hairy Cell Leukemia
Background:
Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, d…
Bethesda, United StatesEst. completion Apr 30, 2028
Hairy Cell Leukemia
Background:
Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene m…
Bethesda, United StatesEst. completion May 20, 2026